List of Excipients in Branded Drug ECOZA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Exeltis USA Dermatology LLC	ECOZA	econazole nitrate	23710-100	BUTANE
Exeltis USA Dermatology LLC	ECOZA	econazole nitrate	23710-100	DIMETHICONE
Exeltis USA Dermatology LLC	ECOZA	econazole nitrate	23710-100	GLYCERIN
Exeltis USA Dermatology LLC	ECOZA	econazole nitrate	23710-100	POLYSORBATE 20
Exeltis USA Dermatology LLC	ECOZA	econazole nitrate	23710-100	POVIDONE K30

ECOZA Excipient Strategy and Commercial Opportunities for Econazole Nitrate Foam

Last updated: August 12, 2026

ECOZA is a differentiated topical antifungal built around a 1% econazole nitrate foam for interdigital tinea pedis. Its commercial value comes less from the active ingredient, which is an established imidazole, and more from the delivery system: rapid-spreading foam, once-daily use, cosmetic acceptability, and access to difficult-to-treat interdigital skin surfaces. The principal excipient opportunity is to preserve foam performance while improving drying time, residue, tolerability, packaging stability, and cost of goods.

What is ECOZA and how is it regulated?

ECOZA contains econazole nitrate 1% and is approved for the topical treatment of interdigital tinea pedis in patients aged 12 years and older. The labeled regimen is once daily for four weeks. It is a prescription drug marketed as a topical foam under an FDA new drug application, not as a biologic or conventional oral generic product.[1]

Attribute	ECOZA profile
Active ingredient	Econazole nitrate
Strength	1%
Dosage form	Topical foam
FDA indication	Interdigital tinea pedis
Labeled population	Adults and pediatric patients aged 12 years and older
Dosing	Once daily for 4 weeks
Regulatory pathway	NDA
Generic pathway	ANDA, subject to applicable FDA requirements
Biosimilar risk	Not applicable
Primary commercial differentiator	Foam vehicle and application experience

The product competes in a mature antifungal market that includes creams, solutions, sprays, powders and over-the-counter products containing terbinafine, clotrimazole, miconazole and tolnaftate. ECOZA’s differentiation depends on delivery performance rather than a new mechanism of action.

What excipients are used in ECOZA foam?

The ECOZA label identifies cetyl alcohol, citric acid, edetate disodium, isopropyl myristate, polysorbate 60, potassium hydroxide, propylene glycol, purified water and stearyl alcohol as inactive ingredients.[1]

Excipient	Likely formulation role	Commercial significance
Cetyl alcohol	Fatty alcohol structurant, emollient and foam stabilizer	Supports cream-like foam texture and residue control
Stearyl alcohol	Fatty alcohol structurant and emollient	Builds viscosity and stabilizes the emulsion matrix
Polysorbate 60	Nonionic surfactant and emulsifier	Helps disperse the lipophilic drug and stabilize the vehicle
Isopropyl myristate	Emollient, solvent and skin-spreading agent	Improves glide and may support drug partitioning into skin
Propylene glycol	Humectant, cosolvent and penetration-supporting excipient	Supports solubilization and wetting; can affect irritation potential
Citric acid	pH adjustment and buffering component	Helps maintain chemical stability and skin compatibility
Potassium hydroxide	pH adjustment and neutralization	Controls vehicle pH and may influence viscosity
Edetate disodium	Chelating agent	Reduces metal-catalyzed degradation pathways
Purified water	Aqueous phase	Controls product feel, evaporation and microbial risk

The combination of cetyl alcohol and stearyl alcohol is important. These fatty alcohols are not simple inactive fillers. They help produce a stable semisolid foam after dispensing and affect collapse time, spreadability, skin feel and residue. Polysorbate 60 and isopropyl myristate support the oil-water balance and the distribution of econazole nitrate within the vehicle.

Propylene glycol has dual commercial importance. It can improve drug solubilization and skin wetting, but excessive concentrations may increase stinging or irritation in compromised skin. That tradeoff matters for tinea pedis, where fissuring, maceration and inflammation can increase sensitivity.

How does the ECOZA excipient system support drug delivery?

Econazole nitrate is a poorly water-soluble, lipophilic compound. A topical formulation must distribute the drug across the skin surface and support partitioning into the stratum corneum. ECOZA’s excipient system addresses that problem through four design functions.

Drug dispersion and solubilization

Polysorbate 60, propylene glycol and isopropyl myristate create a mixed solvent and surfactant environment for econazole nitrate. The formulation does not rely on water alone to carry the active ingredient. The lipophilic vehicle components can improve drug distribution over the skin and reduce visible crystallization.

Foam generation and collapse

The product is dispensed as a foam rather than a conventional cream. The foam must remain coherent during application but collapse quickly enough to leave a continuous drug film. Fatty alcohols and surfactants control this transition. Excessive structural strength would reduce spreadability; insufficient structure could produce run-off, uneven dosing or poor consumer acceptance.

Skin residence and sensory performance

Isopropyl myristate and the fatty alcohols influence skin slip, residual film and perceived greasiness. For a foot product, these characteristics affect adherence. A vehicle that dries quickly and leaves limited residue can be commercially stronger than a thicker cream even when antifungal efficacy is similar.

Chemical and physical stability

Citric acid, potassium hydroxide and edetate disodium provide pH and metal-ion control. Stability risks include drug precipitation, phase separation, viscosity drift, foam collapse, odor changes and packaging-related performance loss. The excipient system must remain stable across the product’s labeled storage conditions and throughout canister life.

What formulation patents may protect ECOZA?

Protection for a topical foam can extend beyond the econazole molecule. Relevant patent categories include:

1. Foam composition claims covering the combination of econazole nitrate with specific solvents, surfactants, fatty alcohols and aqueous phases.
2. Drug-product claims covering a 1% econazole nitrate foam.
3. Manufacturing claims covering preparation, homogenization, filling and propellant charging.
4. Container-closure claims covering the canister, valve, actuator and dose delivery system.
5. Method-of-use claims covering treatment of tinea pedis with the foam.

The commercial importance of these claims depends on their scope, expiration, terminal disclaimers, patent-term adjustment and Orange Book listing status. A generic manufacturer would normally assess whether an ANDA can use the same or an equivalent formulation, whether the reference product’s dosage form can be replicated, and whether a Paragraph IV certification is required for listed patents.

What is the Orange Book status of ECOZA?

ECOZA is associated with FDA NDA 203084 in public FDA drug-product records.[2] The Orange Book is the controlling source for listed patents, use codes, exclusivity and therapeutic-equivalence information. The relevant regulatory question is not whether econazole itself is old. It is whether an ANDA applicant can legally and technically enter with a product that satisfies the reference-listed-drug requirements while addressing any listed formulation or method-of-use patents.

A generic applicant may pursue:

• Paragraph III certification for patents that remain in force.
• Paragraph IV certification alleging non-infringement, invalidity or unenforceability.
• A carve-out for protected use claims, where permitted.
• A formulation that differs from ECOZA while remaining pharmaceutically equivalent and acceptable to FDA.

When does ECOZA lose exclusivity?

ECOZA’s small-molecule exclusivity is distinct from patent protection. FDA regulatory exclusivity may have expired or may no longer be the principal barrier, given the product’s 2013 approval date. The remaining commercial barrier is more likely to involve listed patents, formulation complexity, manufacturing know-how and market economics than NCE exclusivity.

The relevant entry date must be calculated from the current Orange Book patent and exclusivity records, including any patent-term adjustment or pediatric extension. A precise expiration date should not be inferred from the original approval date alone.

How strong is the ECOZA patent estate?

The patent estate is potentially stronger against exact-copy products than against technically differentiated topical formulations.

Risk area	Relative barrier	Reason
Econazole active ingredient	Low	Established generic active
1% topical strength	Low to moderate	Common strength; limited stand-alone differentiation
Foam dosage form	Moderate	Requires specialized vehicle and packaging
Specific excipient combination	Moderate to high	May create formulation claim and development barriers
Manufacturing process	Moderate	Scale-up and reproducibility can be difficult
Container-closure system	Moderate	Valve and canister performance affect dose delivery
Method of use	Low to moderate	Tinea pedis use is commercially important but may be difficult to enforce broadly
Clinical substitution	Moderate	Foam may not be automatically substitutable with a cream

The strongest practical protection may come from the integration of formulation, filling process and package performance. A patent that claims only a broad topical antifungal composition may face validity and design-around pressure. A narrower claim directed to a defined foam structure, excipient ratio or delivery profile may be more defensible but easier to avoid with a modified vehicle.

What generic entry risks exist for ECOZA?

Generic entry is technically feasible but not frictionless. The principal risks are formulation equivalence and commercial scale.

Paragraph IV challenge risk

An ANDA applicant could challenge listed patents through Paragraph IV certifications. The likely targets would be formulation and foam-composition claims rather than the econazole molecule. A successful challenge could accelerate entry if the applicant establishes non-infringement, invalidity or unenforceability.

Litigation risk is highest where the reference product has several listed patents with overlapping claim scope. A settlement could delay entry to a negotiated date, permit an authorized generic, or provide a license under specified conditions. No settlement should be assumed without a confirmed public agreement or court record.

Pharmaceutical equivalence

A generic foam must address:

• Econazole nitrate identity and strength.
• Dosage-form equivalence.
• Drug release and availability from the vehicle.
• Microbiological quality.
• Container-closure performance.
• Delivered dose consistency.
• Stability after repeated dispensing.
• In-use performance over the labeled treatment period.

A cream or solution containing econazole would not necessarily be therapeutically or pharmaceutically equivalent to ECOZA. Such a product could compete commercially but would not automatically substitute for the reference foam through standard generic substitution.

Manufacturing barriers

Foam manufacturing can require controlled mixing, temperature management, emulsion formation, deaeration and specialized filling. The canister and valve must maintain consistent discharge characteristics. Small changes in fatty alcohol particle size, surfactant grade, water content or neutralization can alter foam density and collapse time.

These controls create a manufacturing barrier even when the formula appears simple on paper. Contract manufacturers with topical aerosol capability may be better positioned than conventional cream manufacturers.

What excipient improvements could create commercial opportunities?

The most attractive opportunities are incremental reformulations that preserve the foam’s clinical and regulatory identity while improving patient use.

Low-irritation formulation

A lower-irritancy version could reduce propylene glycol exposure, adjust pH, or modify surfactant concentration. The commercial target would be patients with fissured, inflamed or sensitive interdigital skin. Any change would require assessment of drug solubility, release, stability and dermatologic tolerability.

Faster-drying foam

Reducing residual oiliness could improve adherence and reduce patient complaints about socks, footwear and bedding contamination. The formulation challenge is maintaining sufficient drug deposition while limiting excessive emollient residue.

Potential development levers include:

• Lowering or replacing part of the isopropyl myristate phase.
• Adjusting fatty alcohol ratios.
• Optimizing volatile co-solvent content, where regulatory and safety limits permit.
• Redesigning foam density and collapse time.
• Improving actuator geometry.

Non-aerosol dispensing

A metered, non-aerosol pump could reduce dependence on propellant supply chains and simplify shipping. The tradeoff is that non-aerosol systems may produce a different foam structure and require new dose-delivery validation.

This opportunity could support a new product presentation, but it may also create a separate regulatory and patent position rather than a simple line extension.

Unit-dose or travel format

Unit-dose sachets, small canisters or travel packs could target adherence and convenience. These formats may be attractive for dermatology practices, athletic populations and managed-care sampling. Packaging changes would need to protect the formulation from moisture loss, leakage and dose inconsistency.

Combination antifungal and anti-inflammatory products

A combination product with a corticosteroid could address inflamed fungal infections, but it would introduce regulatory, safety and clinical complexity. It could also create a larger patent opportunity through a new composition and treatment indication. The risk is that corticosteroid use may be inappropriate for prolonged or undiagnosed fungal disease.

OTC-oriented platform

An OTC transition would require a different regulatory strategy, labeling suitable for self-diagnosis and treatment, consumer-use data and compliance with applicable OTC antifungal requirements. Econazole is not a routine U.S. OTC antifungal active, so a switch would involve more than changing packaging.

How does ECOZA compare with competing antifungal dosage forms?

Product type	Main advantage	Main weakness	Competitive implication
ECOZA foam	Fast spreading, differentiated feel, once-daily dosing	Higher manufacturing and packaging complexity	Premium topical positioning
Econazole cream	Familiar and potentially lower cost	Greasier, slower application	Strong generic price competition
Terbinafine cream or spray	Strong consumer awareness and short-course positioning	Different active and labeling profile	Major OTC competitor
Clotrimazole cream	Broad availability and low price	Frequent application for some products	Price-driven substitution risk
Miconazole powder	Moisture management and footwear use	Less suitable for continuous skin film	Complementary rather than direct competition
Topical solutions	Low residue and rapid drying	May sting or spread unevenly	Compete on convenience and drying time

ECOZA is best positioned as a premium convenience product rather than as a lowest-cost antifungal. Its pricing power depends on whether prescribers and patients value foam application enough to offset generic cream alternatives.

Which companies could challenge or compete with ECOZA?

Competition can arise from three groups:

1. Generic manufacturers developing econazole foam or an equivalent topical product.
2. Established topical manufacturers selling econazole creams, solutions or sprays.
3. OTC brands selling terbinafine, clotrimazole and miconazole products.

Companies with topical semisolid, aerosol or dermatology manufacturing capabilities have the strongest technical position. The most credible challenger may not copy the exact foam. It may launch a lower-cost cream or a faster-drying solution and compete for the same prescription or patient population.

What is the revenue exposure and commercial upside?

ECOZA’s revenue exposure is concentrated in the U.S. prescription tinea pedis market. The product has limited indication breadth because the labeled use is interdigital tinea pedis rather than all superficial fungal infections. Revenue therefore depends on prescription volume, formulary coverage, price relative to econazole cream and patient persistence through the four-week course.

The main commercial upside is a protected premium for:

• Once-daily use.
• Cleaner application.
• Rapid spreading.
• Reduced perceived greasiness.
• Dermatology positioning.
• Differentiated packaging.
• Potential line extensions using the same foam platform.

The main downside is substitution. Because the active ingredient is old and multiple topical antifungal alternatives are available, payers and pharmacies can pressure pricing once an equivalent generic or lower-cost competing dosage form becomes available.

What licensing opportunities exist for ECOZA technology?

The most plausible licensing opportunities involve the formulation platform rather than econazole itself.

Platform licensing

A foam vehicle with validated skin delivery, stability and packaging could be adapted for other dermatology actives, including corticosteroids, antibiotics, keratolytics and other antifungals. A platform license could generate value from:

• Formulation know-how.
• Aerosol filling processes.
• Valve and actuator specifications.
• Stability protocols.
• Dermatology clinical data.
• Manufacturing scale-up experience.

Regional licensing

Rights could be divided by territory where prescription antifungal markets, regulatory standards and local manufacturing economics differ. The United States remains the most relevant market for ECOZA’s original NDA, while other jurisdictions may support separate registrations or reformulations.

Authorized generic or supply agreements

A commercial agreement with a generic manufacturer could preserve manufacturing utilization and broaden access after patent barriers weaken. The value would depend on the ability to maintain foam quality at lower cost and avoid cannibalizing the branded product.

Key Takeaways

• ECOZA is a 1% econazole nitrate prescription foam approved for interdigital tinea pedis in patients aged 12 years and older.
• The excipient system uses fatty alcohols, surfactants, propylene glycol, isopropyl myristate, pH adjusters, a chelating agent and water.
• Its commercial differentiation is the foam vehicle, application experience and once-daily regimen, not the novelty of econazole.
• The strongest practical barriers are formulation reproducibility, foam performance, packaging and manufacturing scale-up.
• Generic entry would likely focus on formulation patents and ANDA equivalence rather than the econazole molecule.
• Biosimilar competition is irrelevant because ECOZA is a small-molecule topical drug.
• The best commercial opportunities are low-irritation, faster-drying, non-aerosol, unit-dose and platform-based dermatology formulations.
• Premium pricing is vulnerable to econazole creams and lower-cost antifungal alternatives.
• The Orange Book and associated court records control the current patent, exclusivity and litigation analysis.

FAQs

Can ECOZA excipients be used in a generic econazole cream?

Some excipients may be used, but the generic product would need to satisfy the applicable formulation, quality, equivalence and labeling requirements. Using the same excipients does not automatically establish equivalence or avoid patent claims.

Does the ECOZA foam provide better antifungal efficacy than econazole cream?

The active ingredient and strength are the same, but the foam may improve application, coverage and adherence. The dosage form alone does not establish superior antifungal efficacy across products.

Is isopropyl myristate essential to ECOZA performance?

It is likely important for spreading, emollience and drug partitioning, but an alternative formulation could potentially replace or reduce it if the product maintains stability, release and skin performance.

Could ECOZA be reformulated as a metered-dose pump?

A metered-dose pump could be technically feasible, but it would require development work for foam generation, delivered-dose uniformity, stability, packaging and regulatory comparability.

Can an OTC company launch an econazole foam without infringing ECOZA patents?

Potentially, but the company would need to assess the current Orange Book listings, claim scope, FDA pathway, use labeling and any formulation or container-closure patents. OTC status would not eliminate patent liability.

References

1. U.S. Food and Drug Administration. (2013). Ecoza (econazole nitrate) foam, 1%: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. National Library of Medicine. (n.d.). DailyMed: Ecoza, econazole nitrate foam. U.S. National Library of Medicine.

4. U.S. Food and Drug Administration. (1999). ANDAs for certain highly purified synthetic peptides prepared by chemical processes: Guidance for industry. FDA.